Subacute sclerosing panencephalitis: Combined treatment with interferon alpha and intraventricular ribavirin;Panencefalitis esclerosante subaguda: Tratamiento combinado con interferón alfa y ribavirina intraventricular

Revista de Neurologia

Volumn 42, Issue 5, 2006, Pages 277-281

  Del Toro Riera, Mireia ^a   Macaya Ruiz, A ^a   Raspall Chaure, M ^a   Tallada Serra, M ^a   Pasqual Lopez I ^a   Roig Quilis, M ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Interferon alpha; Measles infection; Ribavirin; Subacute sclerosing panencephalitis

Indexed keywords

ALPHA INTERFERON; METHISOPRINOL; RIBAVIRIN; ANTIVIRUS AGENT;

ANAMNESIS; ARTICLE; CASE REPORT; CHILD; CLINICAL FEATURE; DISEASE COURSE; ELECTROENCEPHALOGRAM; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SUBACUTE SCLEROSING PANENCEPHALITIS; TREATMENT OUTCOME; DRUG COMBINATION; FATALITY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MEASLES; MEASLES VIRUS; METABOLISM; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FATAL OUTCOME; HUMANS; INJECTIONS, INTRAVENTRICULAR; INTERFERON-ALPHA; MALE; MEASLES; MEASLES VIRUS; RIBAVIRIN; SUBACUTE SCLEROSING PANENCEPHALITIS; TREATMENT OUTCOME;

EID: 33749160167     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4205.2005415     Document Type: Article

References (26)

1. Gascón GG. Panencefalitis esclerosante subaguda: actualización 1997. Rev Neurol 1997; 25: 945-53.
2. Grippo J, Cáceres L, Asís A, Grippo T, Ruprecht B, López M. Panencefalitis esclerosante subaguda: forma fulminante. Rev Neurol 2003; 36: 536-9.
3. Jabbour JT, Dueñas DA, Modlin J. SSPE: clinical staging, course and frequency. Arch Neurol 1975; 32: 493-4.
4. Haslam RHA, McQuillen MP, Clark DB. Amantidine therapy in subacute sclerosing panencephalitis. Neurology 1969; 19: 1080-5.
5. Robertson WC, Clark DB, Markesberg WR. Review of 38 cases of subacute sclerosing panencephalitis: effect of amantidine on the natural course of the disease. Ann Neurol 1980; 8: 422-5.
6. Jones CE, Dycken PR, Huttenlocher PR, Jabbour JT, Maxwell KM. Inosiplex therapy in subacute sclerosing panencephalitis, a multi-center, non-randomized study in 98 patients. Lancet 1982; 1: 1034-7.
7. Fukuyama Y, Nihei I, Matsumoto S, Ebina J, Kamoshita S, Sato T, et al. The Inosiplex-SSPE Research Comittee. Clinical effects of MDN-19 (Inosiplex) on subacute sclerosing panencephalitis: a multi-institutional collective study. Brain Dev 1987; 9: 270-82.
8. Smith RA, Kingsbury D, Alksne J. Distribution of interferon in cerebrospinal fluid after systemic, intrathecal and intraventricular administration. Ann Neurol 1982; 12: 81.
9. Panitch HS, Gómez-Plascencia J, Norris FH, Cantell K, Smith RA. Subacute sclerosing panencephalitis: remission after treatment with intraventricular interferon. Neurology 1986; 36: 562-6.
10. Huttenlocher PR, Picchietti DL, Roos RP, Cashman NR, Horowitz B, Horowitz MS. Intrathecal interferon in subacute sclerosing panencephalitis. Ann Neurol 1986; 19: 303-5.
11. Maimone D, Grimaldi LM, Incorpora G, Biondi R, Sofia V, Mancuso GR, et al. Intrathecal interferon in subacute sclerosing panencephalitis. Acta Neurol Scand 1988; 78: 161-6.
12. Steiner I, Wirguin I, Morag A, Abramsky O. Intraventricular interferon treatment for subacute sclerosing panencephalitis. J Child Neurol 1989; 4: 20-4.
13. Kuroki S, Tsutsui T, Yoshioka M, Mizue H, Kita M, Kishida T. The effect of interferon on subacute sclerosing panencephalitis. Brain Dev 1989; 11: 65-9.
14. Yoshioka H, Nishimura O, Nakagawa M, Ochi M, Takeuchi Y, Tominaga M, et al. Administration of human leukocyte interferon to patients with subacute sclerosing panencephalitis. Brain Dev 1989; 11: 302-7.
15. Miyazaki M, Hashimoto T, Fujino K, Goda T, Tayama M, Kuroda Y. Apparent response of subacute sclerosing panencephalitis to intrathecal interferon alpha. Ann Neurol 1991; 29: 97-9.
16. Miyazaki M, Nishimura M, Toda Y, Saijo T, Mori K, Kuroda Y. Longterm follow-up of a patient with subacute sclerosing panencephalitis treated with intrathecal interferon alpha. Brain Dev 2005; 27: 301-3.
17. Cianchetti C, Marrosu MG, Muntoni C, Fratta A, Zuddar A. Intraventricular alpha interferon in subacute sclerosing panencephalitis. Neurology 1998; 50: 315-6.
18. Yalaz K, Anlar B, Oktem F, Aysum S, Ustacelebi S, Gurcay O, et al. Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology 1992; 42: 488-91.
19. Anlar B, Yalaz K, Oktem F, Gulsen K. Long term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon. Neurology 1997; 48: 526-8.
20. Gascón GG, Yamani S, Crowell J, Stigsby B, Nester M, Kanaan I, et al. Combined oral isoprenosine-alpha interferon therapy for subacute sclerosing panencephalitis. Brain Dev 1993; 15: 346-55.
21. Gascón GG. International Consortium on Subacute Sclerosing Panencephalitis. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study. J Child Neurol 2003; 18: 819-27.
22. Takahashi T, Hosoya M, Kimura K, Ohno K, Mori S, Takahashi K, et al. The cooperative effect of interferon-a and ribavirin on subacute sclerosing panencephalitis (SSPE) virus infections, in vitro and in vivo. Antivir Res 1998; 37: 29-35.
23. Tomoda A, Shiraishi S, Hosoya M, Hamada A, Miike T. Combined treatment with interferon-alpha and ribavirin for subacute sclerosing panencephalitis. Pediatr Neurol 2001; 24: 54-9.
24. Hara S, Kimura H, Hoshino Y, Hayashi N, Negoro T, Okumura A, et al. Combination therapy with intraventricular interferon-a and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. Brain Dev 2003; 25: 367-9.
25. Tomoda A, Nomura K, Shiraishi S, Hamada A, Ohmura T, Hosoya M, et al. Trial of intraventricular ribavirin for subacute sclerosing panencephalitis in Japan. Brain Dev 2003; 27: 514-7.
26. Hosoya M, Mori S, Tomoda A, Mori K, Sawaishi Y, Kinura H, et al. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob Agents Chemoter 2004; 48: 4631-5.